The possible role of Bcl-2 expression of tumors of the uterine cervix

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 323-329

  Protrka, Zoran ^a   Djuric J ^a   Protrka, O ^b   Arsenijevic S ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b Health Center   (Serbia)

Author keywords

Bcl 2; Carcinogenesis; Cervical neoplasia; Immunohistochemistry

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2;

ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

CARCINOMA IN SITU; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 77954408887     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Zha J, Harada H, Osipov K et al. BH3 domain of BAD is required for heterodimerization with Bcl-X(L) and pro-apoptotic activity. J Biol Chem 1997; 272: 24101-24104. (Pubitemid 27418599)
2. Protrka Z, Mitrovic S, Arsenijevic N et al. Her-2 expression in uterine cervix carcinogenesis. J BUON 2007; 12: 91-97. (Pubitemid 46824677)
3. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911. (Pubitemid 29407357)
4. Schlesinger PH, Gross A, Yin XM et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 1997; 94: 1135-1139.
5. Tjalma WA, Weyler JJ, Bogers JJ et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001 ; 97: 223-230.
6. Boise LH, Gonzalez-Garcia M, Postema CE et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608. (Pubitemid 23259741)
7. Van der Heiden MG, Chandel NS, Schumacker PT et al. Bcl-x(L) prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Moll Cell 1999; 3: 159-167.
8. Packham G, White EL, Eischen CM et al. Selective regulation of Bcl-XL by a jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev 1998; 12: 2475-2487. (Pubitemid 28406951)
9. Zha J, Harada H, Yang E et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-L(L). Cell 1996; 87: 619-628.
10. Strasser A, Harris AW, Bath ML et al. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333. (Pubitemid 120029100)
11. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
12. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
13. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805. (Pubitemid 24163411)
14. Kihana T, Tsuda H, Teshima S et al. Prognostic significance of the overexpression of Bcl-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994, 73: 148-153. (Pubitemid 24012735)
15. Chung TK, Cheung TH, Lo WK et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2002; 180: 63-68.
16. Cheng EHY, Levine B, Boise LH et al. Bax- independent inhibition of apoptosis by Bcl-X(L). Nature 1996; 379: 554-556.
17. Nunez G, London L, Hockenberry D et al. Deregulated Bcl-2 expression selectively promotes survival of growth factor-deprived hematopoietic cell lines. J Immunol 1990; 144: 3602-3610. (Pubitemid 20146400)
18. Skimisdottir I, Seidal T, Gerdin E et al. The prognostic importance of p53, Bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002; 12: 265-276. (Pubitemid 34787554)
19. Hove MG, Dinh TV, Hannigan EV et al. Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med 1999; 44: 493-496.
20. Cheung TH, Chung TK, Lo KW et al. Apoptosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Gynecol Oncol 2002; 86: 14-18. (Pubitemid 34757044)
21. Jain D, Srinivasan R, Patel FD, Gupta SK. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003; 88: 22-28. (Pubitemid 36062661)
22. Fonseca-Moutinho JA, Cruz E, Carvalho L et al. Estrogen receptor, progesterone receptor, and Bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer 2004; 14: 911-920. (Pubitemid 39238179)
23. Leng CP, Ming LL. Significance of Bcl-2 and Bax proteins in cervical carcinogenesis. Pathology 2006; 28: 1-5.